104 results about "Vascular problem" patented technology

A compound, as shown in Formula I, is a multi-heterocyclic compound. It has been verified that the compound provided by this invention integrates a novel compound targeting the calcitonin gene-related peptide (CGRP) based on ephedrine. Upon contact with the skin, due to photoactivated cell biological function regulation and the blocking effect of the multi-heterocyclic compound I structure on serotonin receptors, it achieves therapeutic effects on cutaneous vascular malformations and telangiectasia, improves the effectiveness of phototherapy in improving chronic cutaneous vascular diseases, and promotes skin wound healing.

The invention discloses a method for adjusting administration dosage according to adverse reaction risk based on a joint model, and is applied to the field of intelligent medical treatment. In the prior art, the relationship between the sirolimus steady-state valley concentration and the specific adverse reaction cannot be quantified, so that the defect of lack of accurate guidance for clinical medication is caused. Through systematic research, the method determines the individual target valley concentration range through a BKMR model for the first time, obtains individual pharmacokinetic parameters of a patient through a group pharmacokinetic model, and finally determines the medication time and the medication dosage of the patient through Bayesian negative feedback simulation, and the medication time and the medication dosage are used for adjusting a medication scheme. According to the invention, prospective risk prediction of adverse reactions of sirolimus is realized, the treatment safety of children with vascular diseases is remarkably improved, and long-term prognosis of patients is improved.

The application discloses a kind of nnUNet zebra fish juvenile whole brain vascular system segmentation methods based on autonomous data set training, it is related to high-resolution imaging technology, image processing and medical image segmentation field, the method makes full use of zebra fish live transparency and fluorescent label advantage, obtains high-resolution whole brain three-dimensional vascular image data, and constructs high-quality segmentation truth value database by semi-automatic segmentation and artificial correction, training is carried out using nnU-Net deep learning model, realize the three-dimensional automatic segmentation of zebra fish brain vascular system signal.The application method significantly improves the degree of automation and precision of image segmentation, effectively solves the problems of low efficiency, high artificial dependence and poor repeatability of traditional brain vascular segmentation.The method is suitable for large-scale high-throughput data processing, can provide efficient, standardized image processing scheme for zebra fish brain vascular development mechanism and brain vascular disease model research, and has wide application prospect.

A prediction system includes: a terminal; and a processor, communicatively coupled to the processor. The processor is configured to: acquire medical treatment information including images captured at at least one of before, during, immediately after, and after a predetermined period from treatment of a patient with a symptom of a vascular disease; classify a condition of the patient based on a classification image; learn the medical treatment information in association with the condition of the patient; and predict at least one of a treatment effect and a prognosis when treatment intervention is performed for the patient based on a learning result.

The present invention provides methods for treating vascular diseases with hemogenic endothelial cells (HEs) obtained in vitro from pluripotent stem cells. The present invention also provides compositions and methods of producing the HEs.

Quinazoline dione compounds are provided for treating cardiac indications such as hypertrophic cardiomyopathy and diastolic dysfunction. Diseases treated by the methods described herein include, but are not limited to, cardiomyopathy, hypertrophic cardiomyopathy (HCM), abnormal heart rhythms, aortic disease, Marfan syndrome, coronary artery disease, heart attack, heart failure, rheumatic heart disease, peripheral vascular disease, stroke, deep vein thrombosis, and pulmonary embolism.

Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I); and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

In an exemplary example, methods and systems are disclosed herein for treating vascular disease by implanting a stent within a vessel and using intravascular imaging to determine and ensure that the stent is properly implanted and produces the desired and effective results. For example, a system can obtain optical shape sensing data and intravascular imaging data of a vessel. The system can process the optical shape sensing data and the intravascular imaging data to generate three-dimensional models and images of the vessel immediately before and after the stent is implanted in the vessel and make an exact comparison of the before and after images to ensure that the stent is properly implanted and will produce or is producing the desired and effective results. The exact comparison can be based on a derived diameter associated with the location of the stent placement in the vessel, which is based on the generated pre- and post- three-dimensional models.

The present disclosure is directed to compositions comprising between 50% and 95% weight per weight (w / w) of acetic acid, between 0.1% and 5% (w / w) of butyric acid or a derivative thereof, and between 0.1% and 5% (w / w) of Quercetin or a derivative thereof. Further, methods of use such as for the treatment and prevention of a medical condition associated with cancer, inflammatory diseases or disorders, metabolic disorders, obesity, diabetes, high blood pressure, vascular diseases, viral infection, and any combination thereof, in a subject in need thereof are also provided.

The present disclosure relates to engineered phospholipid or lysophospholipid (e.g., sphingosine 1-phosphate (S1P)) chaperones derived from apolipoprotein M (ApoM)-Fc fusion proteins with extended half-life in vivo. The disclosed ApoM-Fc fusion proteins provide a safe, highly efficient and effective way of delivering S1P to endothelial cells and all tissues of the body.

The application discloses a portable detection kit for assisting in predicting a cerebral vascular risk, a blood sample is processed through a sample processing module and input corresponding test paper, a detection result of the test paper is collected by a biological sensing module, and the detection result is calibrated and temporarily stored through an electronic control module, so that a user can acquire the calibrated detection result through a target device in an NFC touch mode and automatically send the calibrated detection result to a cerebral vascular disease monitoring digital platform, cerebral vascular risk prediction is performed by the cerebral vascular disease monitoring digital platform, and the portable detection kit has the beneficial effects of high portability, simple operation and high detection result accuracy.

This invention relates to compositions containing acetic acid, butyric acid, and quercetin, and to the use thereof. This disclosure relates to a composition comprising, by weight, 50% to 95% (w / w) acetic acid, 0.1% to 5% (w / w) butyric acid or its derivatives, and 0.1% to 5% (w / w) quercetin or its derivatives. Furthermore, methods for use in the treatment and prevention of medical conditions associated with cancer, inflammatory diseases or disorders, metabolic disorders, obesity, diabetes, hypertension, vascular diseases, viral infections, and any combination thereof, and for use in subjects in need thereof.

This invention discloses an intestinal fungus Saccharomyces cerevisiae M7015 and its applications belong to the field of microbial technology. Saccharomyces cerevisiae The accession number for M7015 is GDMCC No. 66195. This invention first demonstrated, using a mouse subcutaneous stroma embolism model, that the aforementioned strain can promote angiogenesis; secondly, using mouse and Bama miniature pig myocardial infarction models, it was found that the aforementioned strain can promote collateral angiogenesis in ischemic areas of the heart and improve cardiac function. This invention not only fully elucidates... Saccharomyces cerevisiae M7015 promotes the formation of collateral vessels in the heart and improves cardiac function, and also reveals the broad application prospects of this bacterium in the treatment of vascular diseases.

The present disclosure provides compounds capable of exhibiting effects similar to those of 2-Cys-peroxyredoxin (2-Cys-Prx) in the body with excellent pharmacological effects and reduced side effects such as reduced cytotoxicity, and pharmaceutical uses thereof. The compounds of the present disclosure and their pharmaceutically acceptable salts are useful for the treatment or prevention of vascular diseases, particularly ischemic coronary artery disease, arteriosclerosis, vascular restenosis, or pulmonary arterial hypertension. The compounds of the present invention and their pharmaceutically acceptable salts are particularly useful for the treatment or prevention of pulmonary arterial hypertension. The invention also provides methods of preparing the compounds of the present disclosure.

The invention relates to the technical field of cerebrovascular disease thrombectomy, and discloses an auxiliary device for cerebrovascular disease thrombectomy, which comprises two sliding joint mechanisms and a catheter limiting mechanism. According to the auxiliary device for the thrombectomy operation of the cerebrovascular disease, by means of the relative mobility of the X axis, the Y axis and the Z axis, the catheter positioning capacity at any space position can be achieved, the application range of the device is widened, the shaft body design is adopted, the occupation degree of the operation space can be reduced, and in addition, due to the fact that the auxiliary device is placed on the ground and has the braking capacity at the joints, the operation efficiency is improved. And the working stability is relatively high.

The invention discloses a generative artificial intelligence cerebral artery lesion detection method based on plain-scan brain CT. The method comprises the steps that 1, a plain-scan brain CT image to be processed is acquired; 2, converting the plain scanning brain CT image into a CTA image through an adaptive noise elimination network; and 3, carrying out multi-modal lesion detection on the basis of the CTA image generated in the step 2. According to the method, a CTA image is generated through an adaptive noise elimination network (ANE-NET), and a real-time lesion feature analysis engine (RTAL-FE) is embedded in the generation process, so that real-time classification prediction of lesion types is realized. And furthermore, a detection result is output through a dynamic weight decision model (DWD-M), so that the generation quality and the detection efficiency are remarkably improved. The problems that a traditional method is low in generation quality and lags behind detection are solved, and the method is particularly suitable for low-dose and non-invasive cerebrovascular disease screening scenes and has important clinical application value.

The invention provides a construction method of a hypertension-cerebral hypoperfusion composite cerebral small vascular disease rat model. The construction method comprises the steps of experimental animal and grouping, hypertension model induction, cerebral hypoperfusion model induction and model evaluation system. According to the model, hereditary hypertension is replaced by 'L-NAME-induced drug-induced hypertension', and the model is combined with bilateral carotid artery occlusion surgery, so that clinical common hypertension and cerebral hypoperfusion dual pathological processes are successfully simulated. Compared with an SHR model, drug-induced hypertension is adopted to replace hereditary hypertension, and the method has the remarkable advantages in the aspects of period-cost-controllability-flux, 1, the modeling period is shortened to 8 weeks, and about 2 / 3 of time is saved; (2) the cost of a single animal is less than 1 / 3 of that of SHR, and the method is suitable for large-sample and multi-batch research; (3) the dosage of the L-NAME is adjustable, and the two-way intervention research of'hypertension driving 'and'blood pressure normalization' is supported; background data of the SD rats are complete and sufficient in supply, and multi-center repeated experiments are facilitated.

The present invention discloses the use of a compound of formula I sertaconazole or a pharmaceutically acceptable salt thereof in the preparation of a pharmaceutical composition for preventing or treating oxidative stress-related cardiovascular diseases. Specifically, the present invention relates to the use of said compound in the preparation of a medicament for preventing or treating oxidative stress-related vascular diseases, including but not limited to acute coronary syndrome, alcoholic heart dysfunction, hypoxic pulmonary arterial hypertension, heart failure, drug-induced cardiotoxicity and stroke, especially acute heart failure.

The present disclosure relates to methods and systems for quantifying the vascular pattern using ocular imaging that shows vessel profiles for the detection, prevention, and treatment of diabetic retinopathy and other related ocular vascular diseases.

The present application relates to the technical field of medical monitoring, in particular to a vascular hemodynamic abnormality monitoring system and a pulse wave analysis method thereof, the core of the present application lies in that a flexible piezoelectric sensor array is used to capture human vascular pulse wave signals, the signals are transmitted to a wearable monitoring device for preliminary preprocessing, and then transmitted to a data processing host through a wireless manner, a pulse wave analysis module in the host adopts a multi-level analysis method, including multi-scale signal decomposition and reconstruction, nonlinear feature extraction and pattern recognition, multi-parameter adaptive judgment standard, deep learning feature automatic extraction and multi-site information fusion decision, ensuring the accuracy and comprehensiveness of the analysis, finally, the processing result is transmitted to an application platform to generate a vascular health report, realizing non-invasive continuous monitoring, this innovation effectively fills the gap of the prior art in continuous monitoring, and has important significance for real-time monitoring of vascular health status and prevention of vascular diseases.

Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I); and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

Subject matter of the present invention is an angiotensin-receptor-agonist and / or a precursor thereof for use in the treatment of a disease in a subject, • wherein said disease is selected from the group comprising heart failure, chronic heart failure, acute heart failure (AHF), myocardial infarction (MI), stroke, liver failure, burn injuries, traumatic injuries, severe infection (microbial, viral (e.g. AIDS), parasitic diseases (e.g. Malaria)), SIRS or sepsis, cancer, acute kidney injury (AKI), CNS disorders (e.g. seizures, neurodegenerative diseases), autoimmune diseases, vascular diseases, hypotension and shock, and • wherein said subject has an amount of DPP3 protein and / or DPP3 activity in a sample of bodily fluid that is above a predetermined threshold.

The present disclosure relates generally to the use of medical devices for treating vascular disease. In particular, the present disclosure provides devices and methods for using laser-induced pressure waves generated within a sheath to disrupt intimal and medial calcium within a vessel.

The present invention relates to a therapeutic agent for ischemic angiopathy that is a medicinal composition for treating ischemic angiopathy, the medicinal composition including mesenchymal stem cells as an active ingredient, wherein the therapeutic agent for ischemic angiopathy is characterized by being administered to a patient for whom recanalization therapy of an occluded blood vessel has been ineffective and by the therapeutic effect of the therapeutic agent being improved.

Described herein are compounds of Formula I,wherein the variables are defined herein, their use as activators from AMPK, pharmaceutical compositions containing such compounds and their use to treat, for example, heart failure or peripheral vascular disease.

In exemplary examples, methods and systems for treating vascular disease by implanting a stent within the vasculature and using intravascular imaging to determine and ensure that the stent was property implanted and producing a desirable and effective results is disclosed herein. For example, a system may obtain optical shape sensing data and intravascular imaging data for a blood vessel. The system may process the optical shape sensing data and the intravascular imaging data to generate a three-dimensional model and image of the blood vessel immediately before and immediately after stent implantation into the blood vessel, and perform a precise comparison of the before and after images to ensure that the stent was properly implanted and will produce or is producing a desirable and effective result. The precise comparison may be based on a derived diameter associated with the location at which the stent is placed in the blood vessel based on the generated pre and post generated three-dimensional models.

A computer-implemented method and system for assessing vascular disease is disclosed. The disclosure provides receiving angiography image data, including a plurality of image frames captured over a sampling time-period for a subject; identifying a representative image frame from the plurality of image frames; segmenting the plurality of image frames to isolate a vessel region; inferring a plurality of centerline node points associated with a centerline of the vessel; tracking movement of the plurality of centerline node points between successive centerline node points of the plurality of angiogram image frames; registering each segmented frame of the plurality of image frames to the representative image frame; and determining a flow rate of the vessel based in part on a change in length of the vessel represented in successive registered image frames. In embodiments, resultant measurements and results may be displayed upon one or more user interfaces.

The invention relates to an F base modified von Willebrand factor vWF targeting aptamer and an application of the F base modified von Willebrand factor vWF targeting aptamer. Specifically, the invention provides an F base modified vWF targeting aptamer (AF-BT100), the F base modified vWF targeting aptamer comprises a nucleotide core sequence as shown in SEQ ID NO: 1, and the 5'end and the 3 'end are respectively connected with at least two artificial hydrophobic F bases. The invention also comprises a radionuclide-labeled molecular imaging probe [68Ga] Ga-NOTA-AF-BT100, which can realize specific PET imaging in the focus of atherosclerosis, carotid artery thrombosis and acute myocardial infarction. According to the invention, the integrated application of diagnosis and treatment of the pantovascular diseases based on the same vWF targeting aptamer is realized for the first time, and a new strategy is provided for accurate diagnosis and treatment of the pantovascular diseases.

The application discloses a skin cosmetic method based on pulsed laser, comprising the following steps: S1, obtaining epidermal pigment distribution, dermal collagen density, wrinkle depth and abnormal vascular area through a spectrum confocal microscope and a VISIA skin analyzer; S2, performing epidermal pretreatment by using intense pulsed light, selecting a 500-600 nm or 600-1200 nm wave band according to the skin problem type, an energy density of 8-25 J / cm2 and a pulse width of 2-10 ms; S3, starting deep treatment of pulsed laser after 15-60 s interval; S4, monitoring blood oxygen saturation and melanin index of skin tissue in real time by using a spectrum reflectometer during treatment, and dynamically adjusting light source energy and pulse interval; S5, promoting epidermal repair by using a cold compress gel containing hyaluronic acid in cooperation with an ultrasonic introduction instrument after treatment; and S6, regularly performing curative effect evaluation. The application generates a personalized scheme through multi-dimensional skin detection, utilizes IPL to pretreat epidermal pigment and vascular problems, combines 755 nm / 1064 nm pulsed laser to stimulate collagen regeneration in a deep layer, and realizes collaborative treatment of the epidermis-dermis layer.

This disclosure relates to methods of treating or preventing aneurysms or other vascular diseases of conditions related thereto comprising administering an effective amount of a hydroimidazopyridopyrimidinone derivative or salt thereof to a subject in need thereof. In certain embodiments, the derivative comprises a 2,4,6,7,8,9-hexahydro imidazo[1,2-a]pyrido[3,4-e]pyrimidin-5 (1H)-one core structure comprising substituents. In certain embodiments, the compound is 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexa-hydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one (ONC201 / TIC10), derivative, or salt thereof.